Revelation Biosciences selects Avance Clinical as CRO for Titan Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as CRO for its Phase 2/3 Titan study, which is expected to begin later this year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.